Sathyan et al. found that glioblastoma patients with low miR-21/high SOX2 expression had longer overall survival than those with high miR-21/low SOX2 (15.3 vs. 16.7 months, p = 0.0088), which was in accordance with our results. Here, SOX2 is linked to glioblastoma.